Abstract. Neuroblastoma is the most frequent solid malignancy of children. The most reliable prognostic factor in neuroblastoma is the amplification status of the MYCN oncogene, but exceptions from this rule have been observed. Recently we have demonstrated that keratoepithelin (BIGH3, TGFBI) expression significantly reduces proliferation and invasion of neuroblastomas in vitro and in vivo. In these experiments, we also observed that tissue factor pathway inhibitor 2 (TFPI2, PP5, MSPI), a potent inhibitor of matrix-metalloproteinases, is most prominently up-regulated. As MYCN-amplified neuroblastomas are highly invasive, we sought to determine the interaction between MYCN, keratoepithelin and TFPI2. In this study we provide initial evidence that i) keratoepithelin expression in neuroblastoma inversely correlates with MYCN expression; ii) TFPI2 expression in neuroblastoma also correlates inversely with MYCN expression but positively with keratoepithelin expression and iii) keratoepithelin induces elevated TFPI2 transcript levels in neuroblastoma cells without alterations of MYCN expression.
Introduction
In children, neuroblastoma is the most frequent solid extracranial tumour. It is derived from neural crest-born neuroblasts of the sympathetic nervous system; only 5% being of parasympathetic origin. Despite advances in therapeutic regimens, approximately 40% of all patients and 70% of patients with advanced tumour stages die because of the disease. Today, we know a few genetic and molecular alterations that are considered to correlate with the outcome of neuroblastoma patients. Amplification of the MYCN oncogene, expression of the neurotrophin receptor TrkB, deletions of chromosome 1 and decreased expression of TrkA or activin-A are indicators of a poor prognosis, whereas high expression of TrkA or activin-A improves the prognosis for the patients (1, 2) . Today, the most significant marker is the amplification status of the MYCN oncogene, which is clinically used for patient stratification. MYCN-amplified neuroblastomas are the prototype of highly aggressive, rapidly growing tumors that demand immediate medical intervention (3) .
Aggressive tumours all share the ability to grow rapidly, to induce and recruit blood vessels from the surrounding tissue, and to invade and destroy neighbouring tissues by proteolytic mechanisms. Invasion of blood and lymphatic vessels is a prerequisite for distant metastatic spread of tumour cells. Tumours invade adjacent tissues by degradation of the extra-cellular matrix (ECM), whose major constituents are collagen, elastin, glycosaminoglycans and proteoglycans. A multitude of degrading enzymes can participate in this process, nevertheless, matrix-metalloproteinases (MMPs), of which more than 25 are known so far, are the major players (4) . As remodelling of the ECM is a normal event wherever cells, tissues and organs are developing or migrating, this process is tightly controlled in embryonic and healthy tissues. In the intercellular space, secreted MMPs are usually activated from inactive proenzymes by proteinases and degrade collagen, elastin and other proteins of the ECM. Furthermore, their activity is controlled by TIMPs (tissue inhibitors of metalloproteinases), which are released from the ECM during degradation. TFPI2 (tissue factor pathway inhibitor 2), also known as placental protein 5 (PP5) and matrix-associated serine proteinase inhibitor (MSPI), is a member of the TIMP family and represents a Kunitz-type proteinase inhibitor with homology to TFPI1 (5-7). In contrast to TFPI1, TFPI2 is a highly specific inhibitor of interstitial collagenases and gelatinases such as MMP2 and MMP9, but has very little effect on tissue factor itself (8) . In primary gliomas, TFPI2 up-regulation correlates with a non-invasive phenotype, while low expression correlates with high-grade, and a highly invasive phenotype (9) . Overexpression of TFPI2 in highgrade aggressive glioma cell lines reduces their invasive behaviour (10, 11) .
In recent years, we have been seeking new mechanisms of neuroblastoma progression. We have shown that activin-A is negatively controlled by the MYCN oncogene and inhibits growth of experimental human neuroblastomas by reducing the angiogenic potential of the tumour and up-regulating the ECM molecule keratoepithelin (also known as Bigh3 =TGFß-induced h3) (2, 12) . High expression of keratoepithelin in neuroblastoma is associated with a decrease in proliferation and invasion of neuroblastoma cells in vitro and a dramatic growth reduction of experimental neuroblastomas in vivo (13) . In a global gene expression analysis we found TFPI2 most prominently up-regulated in keratoepithelin-transfected neuroblastoma cells. We therefore sought to determine the relationship between MYCN (as a marker for poor patient outcome), keratoepithelin and TFPI2 in more detail. We here show that expression of keratoepithelin and TFPI2 correlates negatively with high MYCN expression (resulting from gene amplification) in primary human neuroblastoma and in neuroblastoma cell lines and that TFPI2 expression in neuroblastoma correlates positively with keratoepithelin expression. Additionally we show that keratoepithelin expression induces elevated TFPI2 transcript levels despite high MYCN expression and suggest that TFPI2 may be a novel prognostic marker in neuroblastoma.
Materials and methods
If not stated otherwise, all chemicals were purchased from Sigma (Taufkirchen, Germany), Fluka (Buchs, Switzerland), Merck (Schwalbach, Germany) or local suppliers.
Cell culture. All neuroblastoma cells were cultured in RPMI-1640 medium (Cambrex, Verviers, Belgium) containing 1% penicillin/streptomycin and 10% foetal calf serum (Biochrom, Berlin, Germany). Cells transfected with vectors were continuously selected with G418 (100 μg/ml) (Invitrogen, Carlsbad, CA) in the above medium. Cloning of keratoepithelin cDNA and transfection of cells. Neuroblastoma cell line Kelly was transfected with a vector containing keratoepithelin cDNA as previously reported (13) .
RNA isolation. Cells were rinsed once with phosphate-buffered saline (PBS) and harvested with Trizol (Invitrogen, Carlsbad, CA) directly from the culture plate. Further RNA isolation was performed according to the manufacturer's protocol.
cDNA production. For the production of cDNA we used 2 μg total RNA per reaction together with Omniscript reverse transcriptase (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. Primers used were random hexamers (Invitrogen, Carlsbad, CA).
Real-time RT-PCR.
Real-time RT-PCR was performed as described recently (13) . Primers were as follows: KE fwd 5'-tttatcgtaatagcctctgcattga-3', KE rev 5'-catgacagtccccattgggg-3'; TFPI2 fwd 5'-cgatgcttgctggaggataga-3', TFPI2 rev 5'-acactgg tcgtccacactcact-3'; and ß-Actin fwd 5'-gcatcccccaaagttcacaa-3', ß-Actin rev 5'-aggactgggccattctcct-3'. Microarray experiments. Expression profiles of keratoepithelinoverexpressing cells (KB 24) and vector control cells (Kelly vec) were obtained on G4112A whole human genome microarrays (Agilent Technologies, Palo Alto, CA). RNA for this experiment was prepared with the RNeasy kit (Qiagen) as recommended by the manufacturer. Processing of the RNA and labelling was performed according to protocols by Agilent. Each cRNA probe was labelled with Cy3 and Cy5 and hybridized crosswise in a dye-swap fashion to avoid artefacts due to dye irregularities. Each dye combination was hybridized to arrays in 3 replicates; therefore 6 arrays were used for final statistics. The normalization of the raw microarray data was performed with a non-linear loess regression (14) and differentially expressed genes were identified by an ANOVAprocedure (15) . The resulting p-values from the test statistics for significance were adjusted with the Benjamini-Hochberg method to control the false discovery rate (16) .
Primary tumour samples of 68 neuroblastoma patients (stage 1, n=20; stage 2, n=16; stage 3, n=7; stage 4, n=15; and stage 4s, n=10) were analyzed for keratoepithelin expression using Affymetrix U95A microarrays as described previously (17, 18) .
Results

Keratoepithelin and TFPI2 expression correlates negatively with MYCN amplification.
We have recently reported that expression of keratoepithelin in neuroblastoma cell lines causes a change towards a benign phenotype, manifested by the loss of invasive properties and a dramatic decrease in tumour formation in vivo (13) . We therefore sought to determine the molecular network behind this observation.
First, we investigated primary neuroblastoma samples of 68 patients using Affymetrix microarrays. However, we did not detect a correlation between keratoepithelin expression and clinical stages, patient outcome, survival or relapse. Nevertheless, we found an inverse correlation (p<0.05) between keratoepithelin expression and MYCN amplification (Fig. 1a) .
Considering these results, we performed an expression analysis of 24 established and well-characterized neuroblastoma cell lines using multiplex and real-time RT-PCR. Again, we observed down-regulation of keratoepithelin transcripts in MYCN-amplified cell lines compared to those with normal MYCN. The median expression difference between the two groups was approximately 2-fold (Fig. 1b) . As tissue factor pathway inhibitor (TFPI2) is predominantly up-regulated in keratoepithelin-transfected neuroblastoma cells (13), we studied the correlation between TFPI2 expression and MYCN amplification. We performed real-time RT-PCR analyses on the same set of neuroblastoma cell lines and observed a pronounced inverse correlation (Fig. 1c) . The median expression of TFPI2 was approximately 20-fold increased in cell lines with normal MYCN expression (not amplified; n=11) as compared to those with MYCN amplification and high expression (n=13).
Experimental regulation of keratoepithelin and TFPI2 by MYCN.
To study the relation between keratoepithelin, TFPI2 and MYCN in an experimental model, we chose the established cell line Tet2/N (19). This cell line, based on the neuroblastoma cell line Sh-ep, bears the MYCN oncogene under the control of a promoter that can be inactivated by a doxycycline (Dox)-inducible repressor (Tet-off system). The inhibitory effect of Dox on MYCN expression in Tet2/N cells is shown in Fig. 2a . Using real-time RT-PCR analysis, we detected a three-fold and two-fold increase of keratoepithelin transcripts in Tet2/N cells treated with 0.5 μg/ml Dox and 1 μg/ml Dox, respectively, as compared to the untreated (0 μg/ml Dox) cells (Fig. 2b) . For TFPI2 we obtained a more pronounced dosage-dependent effect. Treatment with 0.5 μg/ml Dox caused a 1.5-fold increase of TFPI2 transcripts whereas 1 μg/ml Dox induced a ~6-fold higher abundance of TFPI2 mRNA (Fig. 2c) . In summary, both keratoepithelin and TFPI2 mRNA levels increased when MYCN expression was reduced. the interdependence between TFPI2 and keratoepithelin, we studied TFPI2 transcript levels in 24 well-established neuroblastoma cell lines with low (n=17) and high (n=7) expression levels of keratoepithelin (as a reference cell line we used Kelly, which was the cell line used for transfection experiments). We found the median TFPI2 expression to be approximately 10-times higher in cell lines with high keratoepithelin mRNA abundance (Fig. 3a) .
Keratoepithelin up-regulates TFPI2 independently of MYCN levels. To further elucidate the interactions of MYCN, TFPI2
and keratoepithelin, we performed real-time RT-PCR analyses of MYCN-amplified Kelly neuroblastoma cells stably transfected with keratoepithelin cDNA (Fig. 3b) . Two clonal transfectants with moderate (KB16) and high (KB24) keratoepithelin expression were chosen and compared to vectortransfected cells (vec) and wild-type (wt) Kelly cells. TFPI2 expression increased with the amount of keratoepithelin expression of the cells. KB24 cells exhibited an approximately 6-fold and 3-fold increase in TFPI2 compared to wt and vec cells, respectively. The moderately keratoepithelin-expressing cell line KB16 only exhibited a moderate increase in TFPI2 (Fig. 3b) . The results confirm a dose-dependent up-regulation of TFPI2 by keratoepithelin by a cell line, which bears approximately 100 copies of MYCN.
To the best of our knowledge this is the first evidence that i) MYCN down-regulates keratoepithelin levels in neuroblastoma, ii) keratoepithelin has a positive effect on TFPI2 expression and iii) MYCN is a negative regulator of TFPI2, presumably via its negative effects on keratoepithelin.
Discussion
The overexpression of MYCN, mainly caused by amplification of the gene, is of great prognostic value for the patients as these tumours are usually fast growing and aggressive (1, 3) . The physiological role of MYCN in neuronal development is to accelerate the growth of precursor cell populations and retain them in an undifferentiated state (20, 21) . As neuroblastoma is derived from sympathetic embryonic neuroblasts this function holds also true for the tumour cells. High proliferative and migratory activity is of great importance during early-stage embryogenesis when sympathicoblasts migrate as neural crest cells into distant areas of the embryo. However, when the cells have reached their final destination, differentiation takes place, which may be controlled by local cues. Finally, only those sympathicoblasts survive, which have obviously established functional networks. A massive decrease of the size of sympathetic paraganglia then takes place, which can be observed in children of 18 months of age. The mechanisms that regulate development and differentiation of sympathicoblasts are not fully understood, as neither is the great heterogeneity of neuroblastoma behaviour and progression.
MYCN and keratoepithelin are inversely regulated in neuroblastoma.
We have recently shown that expression of keratoepithelin in neuroblastoma cell lines with MYCN amplification leads to a decrease in proliferation and invasion, and inhibition of tumour growth in nude mice (13) . Keratoepithelin is an extra-cellular matrix (ECM) constituent that forms fibrillar structures and interacts with type-I collagen, laminin, fibronectin and integrins (22) (23) (24) (25) (26) . Keratoepithelin can change tumour behaviour to a more benign phenotype whereas amplification of MYCN is the most unfavourable marker in neuroblastoma. We therefore tried to elucidate the interdependence of keratoepithelin and MYCN.
We used samples from 68 neuroblastoma patients and compared their expression profiles on Affymetrix microarrays. Although we could not find a significant correlation between keratoepithelin expression and clinical stages, patient outcome, survival or relapse, we were able to demonstrate a significant negative correlation (p<0.05) with the amplification status of the MYCN oncogene. We sought to verify this result by investigating neuroblastoma cell lines. In 24 neuroblastoma cell lines studied by real-time RT-PCR we have found that the median expression level of keratoepithelin is approximately two-fold higher when the MYCN gene shows a normal diploid state, as compared to cell lines with MYCN amplification. Besides these correlative data, our study shows the regulatory effects of MYCN on keratoepithelin in an experimental model of in vitro MYCN down-regulation, using Tet2/N cells, which express MYCN under the control of a tetracycline-repressible promoter. These cells are derived from the neuroblastoma cell line Sh-ep, which expresses keratoepithelin under normal culture conditions. These experiments confirm the initial findings of our microarray data and suggest that keratoepithelin is a target of MYCN. We show that the two molecules, which have opposing effects on cell proliferation and differentiation, are inversely regulated. The fact that keratoepithelin expression does not show a positive correlation with patient outcome, survival or relapse may be difficult to explain since we have previously shown that its expression reduces the malignancy of neuroblastoma cell lines dramatically (13) . However, a likely explanation is that neuroblastomas with high levels of keratoepithelin are not aggressive and belong to those that differentiate, regress and never become clinically evident. Conflicting results have been reported by Alaminos and colleagues (27) . Solely based on microarray data, they have previously reported that keratoepithelin (referred to as Tgfbi) is up-regulated in neuroblastomas with high MYCN expression. We do not agree with these findings.
MYCN and TFPI2 are inversely regulated in neuroblastoma.
Tumour progression depends on the capability of tumour cells to invade adjacent healthy tissue and form local or distant metastases. Invasiveness of tumour cells is increased by both up-regulation of MMPs and down-regulation of proteinase inhibitors (28) . In neuroblastoma an increased invasive potential has been associated with the expression of MMP2 (29) . MMP2 is a collagenase with high specificity for type-IV and type-I collagen. Its activity is fine tuned by both activators and inhibitors (30) . TFPI2 is a strong inhibitor of MMPs, specifically MMP2 and MMP9. Recent studies have suggested that down-regulation of TFPI2 may be a prognostic marker, as hypermethylation of TFPI2 was reported to occur more frequently in choriocarcinomas, gliomas and cervix carcinoma than in healthy tissue (11, 31, 32) .
We have found that high TFPI2 expression correlates positively with MYCN normoploidy in a set of 24 human neuroblastoma cell lines. Therefore, TFPI2 is not only downregulated in tumour tissues as outlined above, but at least in neuroblastoma, a high TFPI2 expression also correlates with good-prognosis tumours. Thereby TFPI2 may be under direct control of MYCN. Our data provide evidence for the existence of a direct link between MYCN and TFPI2. This has been shown in the Tet2/N model system, which allows downregulation of MYCN by Dox. Administration of Dox reduces the level of MYCN transcripts, while TFPI2 expression increases.
Keratoepithelin up-regulates TFPI2 in neuroblastoma. Since both keratoepithelin and TFPI2 were regulated by MYCN in our experiments, we sought to determine if there is a direct interaction between the two molecules. We compared TFPI2 transcript abundance in keratoepithelin-expressing and nonexpressing human neuroblastoma cell lines and found a significant positive correlation between both molecules. In a second approach, we studied the keratoepithelin-transfected cell lines KB16 and KB24 and compared them to the parental cell line Kelly and vector controls, all harbouring approximately 100 copies of MYCN. In summary, our data show that TFPI2 mRNA levels increase upon keratoepithelin expression, providing evidence for an MYCN-independent regulation of TFPI2 by keratoepithelin. Therefore, TFPI2 as a central regulator of tumour cell invasiveness is regulated at least two-fold, negatively by MYCN expression and positively by keratoepithelin expression. The data are schematically summarized in Fig. 4 .
Taken together, we provide the first evidence that i) keratoepithelin expression correlates negatively with MYCN amplification and expression in primary human neuroblastomas and in neuroblastoma cell lines; ii) TFPI2 expression in neuroblastoma also correlates negatively with MYCN expression, but positively with keratoepithelin expression, and iii) keratoepithelin induces elevated TFPI2 transcript levels in cells without alteration of MYCN expression and independent of MYCN amplification. TFPI2, like keratoepithelin, is a constituent of the ECM, which shows that the aggressiveness of MYCN-overexpressing neuroblastoma may not only be a result of increased proliferation and higher consumption of nutrients, but rather due to the changes in the tumour cell environment. We suggest that keratoepithelin can contribute to a less invasive phenotype in neuroblastoma by up-regulating TFPI2, which has a direct inhibitory effect on MMPs. The down-regulation of both keratoepithelin and TFPI2 by MYCN, which correlates with a fast growing, aggressive tumour behaviour, supports this conclusion. Even though these experiments allow a deeper insight into the complex behaviour of neuroblastoma, both keratoepithelin and TFPI2 call for further investigation, as they seem to have the potential to improve stratification and treatment. Still, the mechanism of keratoepithelin-induced up-regulation of TFPI2 needs to be addressed. 
